Prof Boris Hadaschik (University of Duisburg-Essen, Essen, Germany) discusses the latest updates in non-metastatic castration-resistant prostate cancer (nmCRPC) that were presented at the ASCO 2020 virtual meeting.
He begins by outlining the final analyses from the SPARTAN, PROSPER and ARAMIS trials, which are investigating the use apalutamide, enzalutamide and daralutamide, respectively in patients with nmCRPC.
Prof Hadaschik states that these three trials all displayed an overall survival benefit, and discusses the validity of metastasis-free survival as a clinical endpoint.
He also comments on the toxicity profile of these three androgen receptor antagonists, and mentions that daralutamide seems to be the most tolerable for this patient population.
Prof Hadaschik concludes by explaining how these agents fit into the treatment paradigm for nmCRPC.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).